Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
January 16, 2023 07:00 ET
|
Avectas
DUBLIN, Ireland and CAMBRIDGE, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week,...
Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Research Report 2022 Featuring Pfizer, GSK, Daiichi Sankyo, Intellia Therapeutics, Moderna, CureVac, Arcturus Therapeutics, & BioNTech
January 05, 2023 04:03 ET
|
Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity...
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022 08:30 ET
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
Pfizer und BioNTech geben frühe positive Daten aus klinischer Studie mit an Omikron BA.4/BA.5 angepasstem bivalenten Auffrischungsimpfstoff bei Personen ab 18 Jahren bekannt
October 13, 2022 06:45 ET
|
BioNTech SE
Seren von Probandinnen und Probanden, die sieben Tage nach Verabreichung einer 30-µg-Auffrischungsimpfung mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff entnommen wurden,...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022 06:45 ET
|
BioNTech SE
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in the Omicron BA.4/BA.5...
BioNTech Establishes Asia-Pacific Clinical Scale mRNA Manufacturing & Regional Research Centre
October 07, 2022 09:00 ET
|
mRNA Victoria
MELBOURNE, Australia, Oct. 07, 2022 (GLOBE NEWSWIRE) -- mRNA Victoria announces that the developers of the Pfizer/BioNTech COVID-19 mRNA vaccine will also establish an Asia-Pacific mRNA clinical...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022 08:45 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
BioNTech CEO Ugur Sahin besuchte Israel: Diskussion möglicher Zusammenarbeit bei der Pandemievorsorge und der Entwicklung innovativer Medikamente
September 07, 2022 02:00 ET
|
BioNTech SE
JERUSALEM, Israel, und MAINZ, Deutschland, 7. September 2022 — BioNTech SE (Nasdaq: BNTX, „BioNTech“) gab heute bekannt, dass Prof. Ugur Sahin, CEO und Mitbegründer von BioNTech, nach Israel gereist...
BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
September 07, 2022 02:00 ET
|
BioNTech SE
JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech, visited Israel to meet with the Minister of...